Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Rebif

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Rebif was produced by Merck KGaA.

Tackling a formidable foe

Tackling a formidable foe

Formidable foe. “With Rebif (interferon beta-1a), Merck’s legacy MS therapy approved in Europe 20 years ago, one of the innovations is the ability to have auto-injectors and devices

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding Teva’s Copaxone, Biogen’s Avonex and Merck Serono’s Rebif have all been accepted for routine use on the NHS after the companies agreed to lower their prices – in addition

Roche’s Ocrevus is first primary progressive MS drug in EU

Roche’s Ocrevus is first primary progressive MS drug in EU One reason for the rapid take-up is clinical data showing that Ocrevus is more effective in relapsing MS than Merck KGaA’s beta interferon drug Rebif, as well as competitive

Novartis’ Extavia evades NICE restrictions on MS drugs

Novartis’ Extavia evades NICE restrictions on MS drugs But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down. ... The appraisal rejected four other interferons - Biogen’s Avonex and long-acting variant Plegridy, Bayer’s Betaferon, and Merck Serono’s Rebif - as well as Teva’s

Ocrevus off to a flying start as Roche raises 2017 forecasts

Ocrevus off to a flying start as Roche raises 2017 forecasts The take-up of the drug has been buoyed by trials showing that the drug outperformed Merck KGaA's MS stalwart Rebif (interferon beta-1a) in two relapsing MS phase III

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics